Anavex Life Sciences Corp. (AVXL) — SEC Filings
Anavex Life Sciences Corp. (AVXL) — 20 SEC filings. Latest: 8-K (May 6, 2026). Includes 7 8-K, 6 10-Q, 3 SC 13G/A.
View Anavex Life Sciences Corp. on SEC EDGAR
Overview
Anavex Life Sciences Corp. (AVXL) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K filed on Nov 25, 2025: ANAVEX LIFE SCIENCES CORP. (AVXL) is a clinical-stage biopharmaceutical company focused on CNS diseases. For the fiscal year ended September 30, 2025, the company reported no revenue, consistent with its clinical-stage status. A key business change was the submission of a Marketing Authorisation App
Sentiment Summary
Across 20 filings, the sentiment breakdown is: 2 bearish, 18 neutral. The dominant filing sentiment for Anavex Life Sciences Corp. is neutral.
Filing Type Overview
Anavex Life Sciences Corp. (AVXL) has filed 7 8-K, 2 10-K, 6 10-Q, 2 DEF 14A, 3 SC 13G/A with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (20)
Risk Profile
Risk Assessment: Of AVXL's 14 recent filings, 2 were flagged as high-risk, 10 as medium-risk, and 2 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | N/A |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | N/A |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Dr. Ole Jensen
- Dr. David M. Bear
- Michael J Fox
Industry Context
The biopharmaceutical industry, particularly the segment focused on central nervous system (CNS) diseases, is characterized by high unmet medical needs and significant R&D investment. Companies are increasingly leveraging precision medicine and biomarker identification to develop targeted therapies. The competitive landscape includes both large pharmaceutical companies and smaller, specialized biotech firms, with a strong emphasis on innovation and navigating complex regulatory pathways.
Top Tags
10-Q (5) · Biotechnology (3) · biotech (3) · financials (3) · Clinical Trials (2) · corporate-governance (2) · shareholder-meeting (2) · Financial Report (2) · SEC Filing (2) · Anavex Life Sciences (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Revenue | $0 | The company is a clinical-stage biopharmaceutical company and reported no revenue for the fiscal year ended September 30, 2025. |
| Date of EMA Negative Trend Vote | November 14, 2025 | The CHMP of the EMA informed Anavex of a negative trend vote on the MAA for blarcamesine, a critical regulatory development. |
| Expected Formal CHMP Opinion | December 2025 | The CHMP is expected to adopt a formal opinion on the MAA at its December 2025 meeting, following the negative trend vote. |
| Slowed Clinical Progression (ADAS-Cog13) | 36.3% | Blarcamesine slowed clinical progression by 36.3% at 48 weeks in the Phase 2b/3 trial for early Alzheimer's disease, compared to placebo (P = 0.0079). |
| CDR-SB Improvement vs. Placebo | 0.483 | The key secondary endpoint CDR-SB was significantly improved vs. placebo (P = 0.0104) in the Phase 2b/3 trial. |
| Reduction in Whole Brain Atrophy | 37.6% | Blarcamesine significantly slowed brain atrophy in key regions, including the whole brain by 37.6%. |
| Duration of ATTENTION-AD Trial | 192 weeks | The long-term open label extension study (ATTENTION-AD) demonstrated continued benefit through up to 192 weeks. |
| SIGMAR1 Wild Type Gene Variant Population | 80% | An estimated 80% of the worldwide population has the common SIGMAR1 wild type gene variant, which showed improved cognitive and functional scores with ANAVEX 2-73. |
| Period End Date | 2025-06-30 | latest financial reporting period |
| SEC File Number | 001-37606 | identifies the company's registration with the SEC |
| Public Documents | 13 | Total number of documents filed with this report. |
| Fiscal Quarter | Q2 2025 | Reporting period ending March 31, 2025 |
| Fiscal Year End | 0930 | Company's fiscal year concludes on September 30th |
| Reporting Period End Date | 2024-12-31 | Indicates the end of the fiscal quarter for which financial information is reported. |
| Filing Date | 2025-02-12 | Shows when the 10-Q was officially submitted to the SEC. |
Frequently Asked Questions
What are the latest SEC filings for Anavex Life Sciences Corp. (AVXL)?
Anavex Life Sciences Corp. has 20 recent SEC filings from Jan 2024 to May 2026, including 7 8-K, 6 10-Q, 3 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of AVXL filings?
Across 20 filings, the sentiment breakdown is: 2 bearish, 18 neutral. The dominant sentiment is neutral.
Where can I find Anavex Life Sciences Corp. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Anavex Life Sciences Corp. (AVXL) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Anavex Life Sciences Corp.?
Key financial highlights from Anavex Life Sciences Corp.'s most recent 10-K include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for AVXL?
The investment thesis for AVXL includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Anavex Life Sciences Corp.?
Key executives identified across Anavex Life Sciences Corp.'s filings include Dr. Ole Jensen, Dr. David M. Bear, Michael J Fox.
What are the main risk factors for Anavex Life Sciences Corp. stock?
Of AVXL's 14 assessed filings, 2 were flagged high-risk, 10 medium-risk, and 2 low-risk.
What are recent predictions and forward guidance from Anavex Life Sciences Corp.?
Forward guidance and predictions for Anavex Life Sciences Corp. are extracted from SEC filings as they are enriched.